{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["48(6)"],"submitter":["Han T"],"pubmed_abstract":["<h4>Purpose</h4>Combining paclitaxel with antiangiogenic agents has demonstrated improved efficacy as second-line treatment for advanced gastric cancer. Surufatinib, a multi-kinase inhibitor with antiangiogenic and immunomodulatory properties, has exhibited synergistic effects with chemotherapy in preclinical studies.<h4>Methods</h4>This single-arm phase 2 trial enrolled patients aged 18-75 with HER2-negative unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma who had failed first-line therapy. All received surufatinib 250 mg once daily plus paclitaxel 150mg/m<sup>2</sup> every 3 weeks for up to 6 cycles, followed by maintenance surufatinib until progression, intolerable toxicity, or withdrawal. The primary endpoint was objective response rate (ORR) per Response Eva"],"journal":["Cellular oncology (Dordrecht, Netherlands)"],"pagination":["2073-2084"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12698750"],"repository":["biostudies-literature"],"pubmed_title":["Surufatinib plus paclitaxel as second-line therapy for advanced gastric cancer: a single-arm, phase 2 clinical trial."],"pmcid":["PMC12698750"],"pubmed_authors":["Zhuo M","Zheng X","Qiu X","Cui J","Wang T","Jiao F","Xiao X","Lin X","Su Y","Han T","Wu X"],"additional_accession":[]},"is_claimable":false,"name":"Surufatinib plus paclitaxel as second-line therapy for advanced gastric cancer: a single-arm, phase 2 clinical trial.","description":"<h4>Purpose</h4>Combining paclitaxel with antiangiogenic agents has demonstrated improved efficacy as second-line treatment for advanced gastric cancer. Surufatinib, a multi-kinase inhibitor with antiangiogenic and immunomodulatory properties, has exhibited synergistic effects with chemotherapy in preclinical studies.<h4>Methods</h4>This single-arm phase 2 trial enrolled patients aged 18-75 with HER2-negative unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma who had failed first-line therapy. All received surufatinib 250 mg once daily plus paclitaxel 150mg/m<sup>2</sup> every 3 weeks for up to 6 cycles, followed by maintenance surufatinib until progression, intolerable toxicity, or withdrawal. The primary endpoint was objective response rate (ORR) per Response Eva","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-06T01:56:18.056Z","creation":"2026-05-24T03:12:22.958Z"},"accession":"S-EPMC12698750","cross_references":{"pubmed":["41182657"],"doi":["10.1007/s13402-025-01127-9"]}}